anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Vitiligo is a common, disfiguring skin complaint which affects between 0.5 and 2% of the world population and which presents with de-pigmented patches of skin. Highly stigmatising it has a profound psychological impact on those affected and negatively impacts quality of life. Efficacy of current therapies which include topical steroids/calcineurin inhibitors and ultraviolet light are limited and new treatments are required. Numerous papers including the 2010 Cochrane review have highlighted the need for a consensus on outcome measures which could then facilitate meta-analyses and provide robust clinical recommendations. No standard method of measuring skin re-pigmentation has been identified to date and current best practice relies on clinician assessment and use of various non-standardised grading systems (of which there are over 40 none of which has been proven superior or accepted by the consensus of clinicians) and in addition are neither robust nor objective. Measurement of skin pigment levels can be achieved using portable devices such as Spectrophotometric Intracutaneous Analysis scope (SIAscope) using an imaging modality called ScanoskinTM. Unlike other digital methods reported in the literature, this has been validated as a quantitative measure of melanin content in the skin, it is portable, easy to use and not prohibitively expensive. The aim of this study is to determine if ScanoskinTM is equivalent to the current gold standard of planimetry (mainly used in research setting) for establishing extent of vitiligo. In addition the investigators want to assess whether it offers a more objective standardised measure of vitiligo compared with clinician assessment (current accepted best clinical practice) which could then be utilised to provide a meaningful assessment of new and existing treatment modalities. In addition the investigators will assess whether ScanoskinTM is able to identify subclinical disease which could affect clinical decisions regarding treatment strategies and also assess whether improvements in pigmentation correlate with patient satisfaction and quality of life scores.
INTRODUCTION: Memory complaints resulting from COVID-19 may have a significant impact on the survivors' quality of life. Unfortunately, there is insufficient information available on memory loss and its relationship to COVID-19. Therefore, the purpose of this research was to determine the prevalence of memory complaints in post-COVID-19 patients and to find potential contributing factors.
METHOD: A cross-sectional survey was conducted on 401 individuals who had previously been diagnosed with COVID-19 at four COVID testing centers situated across Bangladesh. The MAC-Q questionnaire was used to evaluate memory. A binary logistic regression model was fit to study the variables related to memory complaints, with a p-value of <0.05 deemed statistically significant.
RESULT: Memory complaints was prevalent in 19.2% of the post-COVID patients. Individual predictor analysis revealed that among the treatment modalities, steroids and antibiotics were associated with impaired memory. Multiple logistic regression showed that individuals who recovered from COVID-19 within six to twelve months were more likely to have memory deficits. Even though age, sex, oxygen demand, and hospitalization were not linked with memory complaints, rural residents exhibited more significant memory complaints than urban residents.
CONCLUSION: Nearly one-fifth of the COVID-19 patients suffer from various degrees of memory complaints within one year. However, no association was found between COVID-19 severity to memory complaints.
FIELD: agriculture, veterinary science. SUBSTANCE: invention relates to preparing biopreparations used for specific prophylaxis of tuberculosis in animals. Method involves detoxification of endotoxin of cultural fluid with formalin, its sorption on aluminium hydroxide, evaporation of inactive part of anatoxin and sterilization. Cultural fluid of avirulent strain of mycobacterium BCG is used as an endotoxin. Aluminium hydroxide gel is added in the amount 1.9-2 mg/1 ml. Then vacuum evaporation of 60-65% of inactive part of anatoxin is carried out. The end obtained product has concentration of aluminium hydroxide 4 mg/ml, not above, and antigenic activity 190 000-200 000 T.U./ml. EFFECT: enhanced protective effect of anatoxin, absence of expressed toxicity. 1 tbl, 1 ex
BACKGROUND: Aromatase inhibitors have positive impacts on the disease-free life of patients with breast cancer. However, their side effects, especially arthralgia, may be experienced by many patients. This study sought to assess the efficacy of Progressive Relaxation Exercises on the prevalent side effects of Aromatase Inhibitors in patients with breast cancer.
MATERIALS AND METHODS: This clinical trial was conducted with single-blind randomization at a physiotherapy department in a local hospital. Patients who received Aromatase Inhibitor were assigned at random to either the study or control group. The study group (n = 22) performed a Progressive Relaxation Exercises program four days a week for six weeks, while the control group (n = 22) received advice on relaxation for daily life. Data was collected before the intervention and after six weeks. The study's primary endpoint was the Brief Pain Inventory, which was used to measure pain severity. Secondary endpoints included assessments of quality of life and emotional status, which were measured using the Functional Assessment of Chronic Illness Therapy and Hospital Anxiety and Depression scales, respectively.
RESULTS: The study group exhibited a significant reduction in Pain Severity (p = 0.001) and Pain Interference (p = 0.012) sub-scores. Reduction in Pain Severity (p<0.001) and Patient Pain Experience (p = 0.003) sub-scores was also noted between the groups. Quality of Life and Emotional Status showed no significant variation both within and between the groups (p>0.05).
CONCLUSION: The study demonstrated that Progressive Relaxation Exercises caused a significant reduction in pain scores among Breast Cancer patients receiving Aromatase Inhibitors. While a decrease in pain during the 6-week period is valuable data, it is necessary to monitor the long-term effects of relaxation techniques.
In eukaryotic cells, the mammalian target of rapamycin complex 1 (sometimes referred to as the mechanistic target of rapamycin complex 1; mTORC1) orchestrates cellular metabolism in response to environmental energy availability. As a result, at the organismal level, mTORC1 signalling regulates the intake, storage and use of energy by acting as a hub for the actions of nutrients and hormones, such as leptin and insulin, in different cell types. It is therefore unsurprising that deregulated mTORC1 signalling is associated with obesity. Strategies that increase energy expenditure offer therapeutic promise for the treatment of obesity. Here we review current evidence illustrating the critical role of mTORC1 signalling in the regulation of energy expenditure and adaptive thermogenesis through its various effects in neuronal circuits, adipose tissue and skeletal muscle. Understanding how mTORC1 signalling in one organ and cell type affects responses in other organs and cell types could be key to developing better, safer treatments targeting this pathway in obesity.
Subjects in this group were trained with Tai Chi exercise. The training lasted for 12 weeks, one hour per session and twice a week. Subjects were asked to practice outside of the class 30 minutes at least once a week.
Disperse tablet in 60 mL (2 ounces) of non-carbonated water only. Stir until tablet is dispersed into small pieces (the tablet will not completely dissolve) and swallow immediately. Do not crush, heat, or ultrasonicate during preparation. Rinse the container with 120 mL to 240 mL (4 to 8 ounces) of water and immediately drink.

If administration via nasogastric tube is required, disperse the tablet as above in 15 mL of non-carbonated water, and then use an additional 15 mL of water to transfer any residues to the syringe. The resulting 30 mL liquid should be administered as per the nasogastric tube instructions with appropriate water flushes (approximately 30 mL). Repeat this step until no pieces remain in the syringe. This will help to ensure that the full prescribed dose of the TAGRISSO is given. The dispersion and residues should be administered within 30 minutes of the addition of the tablets to water.
The invention relates to magnesium lactate, wherein the lactate is L-lactate, for treating pain. The treatment may comprise topical application of magnesium L-lactate (C6H10MgO6) to the skin. The pain may be chronic, acute, neuropathic, osteoarthritic, or related to trauma. The pain may be also caused by diabetic neuralgia, complex regional pain syndrome, fibromyalgia, or chronic fatigue syndrome. Also claimed is a pain relief composition, analgesic composition, or anodyne composition, comprising magnesium L-lactate. The magnesium L-lactate may be present in the amount 5 to 25 wt.%. The composition may further comprise vitamin D up to 40,000 International Units per ml. The composition may be a topical analgesic in the form of a gel, ointment, lotion, emulsion, cream, foam, mousse, liquid, spray, suspension or aerosol. The composition may also comprise: medium-chain triglycerides; one or more preservatives; a penetration enhancer such as isopropyl myristate; solid aliphatic alcohols; mono- or di-glycerides; and polyoxyethylene alkyl ethers. There may further be cooling additives, such as Boswellia extract and/or eucalyptus essential oil. Alternatively, the composition may comprise warming additives, such as black pepper essential oil, turmeric, and/or capsicum. The invention provides improved bioavailability of magnesium L-lactate to treat pain.
The present disclosure provides a system for the in vivo modification of T cells. The system comprises pools of adenovirus particles that have been modified so that they target T- cells. One pool of adenovirus particles comprises an expression cassette encoding a CAR that recognizes a cancer-associated antigen, flanked by polynucleotide arms for CRISPR-mediated insertion of the expression cassette into a T-cell genome. Other pools of adenovirus particles express components required for CRISPR-mediated insertion of the expression cassette. Administration of the system to an individual results in in vivo modification of T-cells so that they express the CAR. Also provided herein are individual adenoviral vectors and targeted adenoviral particles comprising such vectors, for practicing methods of the disclosure.
The invention provides traditional Chinese medicine granules for treating infectious bronchitis and a preparation method thereof. The traditional Chinese medicine granules comprise the following components in parts by weight: 6-9 parts of honeysuckle, 3-4 parts of semen armeniacae amarae and 1-2 parts of Momordica grosvenori. The traditional Chinese medicine granules are prepared by adding cane sugar after decoction. The traditional Chinese medicine granules with reasonable components of traditional Chinese medicines have the remarkable effect of clearing away heat and toxic materials. An effective therapeutic medicine for treating infectious bronchitis is provided for the poultry industry. The traditional Chinese granules have the characteristics of quick effect, exact curative effect, no medicine residue and no toxic and side effects. The traditional Chinese medicine granules are simple in preparation method, and are suitable for demands of large-scale industrial production.
A method of monitoring a subject, such as a patient, using rules is provided. The method includes receiving data from the subject, and applying the data to a rule-based algorithm. The method also preferably includes generating a response based on the application of the rule-based algorithm. Some examples of responses include generating an alarm, generating a suggested reason for an identification of an abnormal condition, and generating a suggested response to an abnormal condition that has been identified. Preferably, more than one set of variables is applied to a particular rule-based algorithm. A monitor using the method may be configured to have multiple rule-based algorithms selected and applied simultaneously. Each rule-based algorithm can generate a unique response, or a combination can be used to generate a smaller number of responses. Also, a monitor using this method may be configured to allow rule-based algorithms to be exchanged and/or altered.
Patients receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.
The aim of the current study was to investigate interindividual differences in muscle thickness of the rectus femoris (MTRF) following 12 wk of resistance training (RT) or high-intensity interval training (HIIT) to explore the genetic architecture underlying skeletal muscle hypertrophy and to construct predictive models. We conducted musculoskeletal ultrasound assessments of the MTRF response in 440 physically inactive adults after the 12-wk exercise period. A genome-wide association study was used to identify variants associated with the MTRF response, separately for RT and HIIT. Using the polygenic predictor score (PPS), we estimated the genetic contribution to exercise-induced hypertrophy. Predictive models for the MTRF response were constructed using random forest (RF), support vector mac (SVM), and generalized linear model (GLM) in 10 cross-validated approaches. MTRF increased significantly after both RT (8.8%, P < 0.05) and HIIT (5.3%, P < 0.05), but with considerable interindividual differences (RT: -13.5 to 38.4%, HIIT: -14.2 to 30.7%). Eleven lead single-nucleotide polymorphisms in RT and eight lead single-nucleotide polymorphisms in HIIT were identified at a significance level of P < 1 × 10-5. The PPS was associated with the MTRF response, explaining 47.2% of the variation in response to RT and 38.3% of the variation in response to HIIT. Notably, the GLM and SVM predictive models exhibited superior performance compared with RF models (P < 0.05), and the GLM demonstrated optimal performance with an area under curve of 0.809 (95% confidence interval: 0.669-0.949). Factors such as PPS, baseline MTRF, and exercise protocol exerted influence on the MTRF response to exercise, with PPS being the primary contributor. The GLM and SVM predictive model, incorporating both genetic and phenotypic factors, emerged as promising tools for predicting exercise-induced skeletal muscle hypertrophy.NEW & NOTEWORTHY The interindividual variability induced muscle hypertrophy by resistance training (RT) or high-intensity interval training (HIIT) and the associated genetic architecture remain uncertain. We identified genetic variants that underlie RT- or HIIT-induced muscle hypertrophy and established them as pivotal factors influencing the response regardless of the training type. The genetic-phenotype predictive model developed has the potential to identify nonresponders or individuals with low responsiveness before engaging in exercise training.
Group of subjects that have undergone RNS® System implantation that are randomized to receive sham-stimulation (i.e. responsive stimulation disabled or turned OFF) during the blinded Evaluation Period. Stimulation is enabled after transition into the Follow-Up Period (5th month post-implant) and may continue for the remainder of the subject's participation in the study.
Hypoxic-ischemic encephalopathy (HIE) results from a lack of oxygen to the brain during the perinatal period. HIE can lead to mortality and various acute and long-term morbidities. Improved bedside monitoring methods are needed to identify biomarkers of brain health. Functional near-infrared spectroscopy (fNIRS) can assess resting-state functional connectivity (RSFC) at the bedside. We acquired resting-state fNIRS data from 21 neonates with HIE (postmenstrual age [PMA] = 39.96), in 19 neonates the scans were acquired post-therapeutic hypothermia (TH), and from 20 term-born healthy newborns (PMA = 39.93). Twelve HIE neonates also underwent resting-state functional magnetic resonance imaging (fMRI) post-TH. RSFC was calculated as correlation coefficients amongst the time courses for fNIRS and fMRI data, respectively. The fNIRS and fMRI RSFC maps were comparable. RSFC patterns were then measured with graph theory metrics and compared between HIE infants and healthy controls. HIE newborns showed significantly increased clustering coefficients, network efficiency and modularity compared to controls. Using a support vector machine algorithm, RSFC features demonstrated good performance in classifying the HIE and healthy newborns in separate groups. Our results indicate the utility of fNIRS-connectivity patterns as potential biomarkers for HIE and fNIRS as a new bedside tool for newborns with HIE.
BACKGROUND: This study aimed to evaluate the effectiveness of unilateral external oblique intercostal nerve block (EOIB) in laparoscopic cholecystectomy surgery.
MATERIAL AND METHODS: After ethics committee approval, ASA I-II patients aged 18-70 who would undergo laparoscopic cholecystectomy surgery were included in the study. The patients were divided into two groups, external oblique intercostal nerve block (Group EOIB) and oblique subcostal transversus abdominis plane block (Group OSTAP). After surgery, EOIB or OSTAP block was administered with 20 mL of .25% bupivacaine then routine analgesia protocol was applied with iv paracetamol, and tramadol. Visual analog scale (VAS) scores and patient-controlled analgesia (PCA) consumption were monitored 24 hours after the operation. It was administered 25 mg pethidine as a rescue analgesic to patients with VAS ≥4.
RESULTS: Thirty six patients for Group EOIB and thirty four patients for Group OSTAP were included in the study. Lower VAS scores were observed in all groups. When PCA consumption, side effects, rescue analgesia consumption, and patient satisfaction were evaluated, there was no statistically significant difference between the groups (P > .05).
CONCLUSION: It was observed that EOIB showed similar analgesic activity to the OSTAP block. EOIB may also be a part of postoperative multimodal analgesia by reducing postoperative opioid consumption in LC.
Acute kidney injury (AKI) is a frequent complication immediately after heart transplantation (HT), with incidence rates between 40-70%. Several factors contribute to this complication, such as hypervolemia, hyperactivation of renin-angiotensin-aldosterone system (RASS) and low cardiac output. Hypertonic saline solution (HSS) can reduce diuretic resistance, increase urinary output and improve renal function in hypervolemic status such as acute heart failure. Therefore, the investigators hypothesized that the use of HSS could prevent or attenuate AKI after heart transplantation in the early postoperative phase. The investigators aim to randomize 74 patients to receive 150 mL of HSS 3,5% or placebo (saline solution 0,9%) twice daily for 3 days after HT. Renal function, right ventricular echocardiographic parameters and pulmonary artery catheter parameters will be assessed. Patients will be followed-up until 30 days, or death.
After polio eradication, access to live polioviruses will be highly restricted, and oral poliovirus vaccine (OPV) use must be discontinued. OPV-using countries must decide whether to switch to inactivated poliovirus vaccine (IPV) or stop polio vaccination. Because only limited data are available on IPV immunogenicity in tropical developing countries, we conducted a randomized controlled trial of IPV in Cuba. The objectives of this study were to assess the humoral and mucosal immunogenicity conferred by IPV administered at the WHO-EPI schedule (6,10,14 wks of age) vs. placebo. A third arm was added to evaluate the immunogenicity of IPV administered at 2 and 4 months of age. Antibody titers were measured prior to the first dose as well as 1 month after the last dose in each study arm. Target sample size was 100 children in each arm. Mucosal (intestinal immunity) was measured indirectly through assessing poliovirus excretion in each group after a "natural challenge" of trivalent oral polio vaccine (OPV)recieved by study participants through their participation in the annual OPV mass campaigns approximately 1 month after their last dose of vaccine.
<P>PROBLEM TO BE SOLVED: To provide a method for introducing a compound into a cell, by which the compound having a relatively low mol. wt. including a low mol. wt. nucleic acid can simply, safely and efficiently be introduced into the cell in low toxicity without needing special equipment, and to provide a compound carrier therefor.  <P>SOLUTION: The carrier agent for introducing the compound in the cell comprises a compound represented by formula (I) [(m) is 1 or 2; (n) is an integer of 2 to 6]. A complex of the carrier with a compound to be introduced (preferably a low molecular nucleic acid such as siRNA). A method for introducing the compound into the cell comprises bringing the complex into contact with the cell.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
PURPOSE:To provide an excellent cosmetic compound containing a novel active component consisting of silkworm feces containing chlorophyll, minerals, vitamins, enzymes, growth hormones and various other active components of silkworm. CONSTITUTION:A detergent (e.g. soap), face lotion (e.g. milky lotion or lotion) or cosmetic (e.g. cream, foundation or powdery pack) containing silkworm feces as a component. Silkworm feces contains various active components of mulberry tree such as chlorophyll, minerals (e.g. natural calcium) vitamins (e.g. vitamin C), enzymes beneficial to the skin and growth hormones in addition to various active components of silkworm. Although the silkworm feces has alkaline nature, it is harmless to human body. The mildness and affinity of the feces to the skin can be improved by neutralizing or weakly acidifying the feces.
The utility model discloses a direct-administering stick whose main body is stick-shaped. The lateral section of one end of the utility model is round. The length of the main body of the direct-administering stick is 1 to 20 centimeters. The diameter of the main body is 0.5 to 3 millimeters. The direct-administering stick of the utility model is a filemot solid stick-shaped direct-administering stick compounded by povidone iodine and plasticizer. Both the diameter and the length of the utility model are comparative reasonable. Accordingly, patients can use the utility model easily and the utility model facilitates patients' treatment hugely.
In controlled clinical trials, single doses of 20 mg and 40 mg were effective for the acute treatment of migraine in adults. A greater proportion of patients had a response following a 40 mg dose than following a 20 mg dose (see CLINICAL STUDIES). Individuals may vary in response to doses of RELPAX Tablets. The choice of dose should therefore be made on an individual basis. An 80 mg dose, although also effective, was associated with an increased incidence of adverse events. Therefore, the maximum recommended single dose is 40 mg.

If after the initial dose, headache improves but then returns, a repeat dose may be beneficial. If a second dose is required, it should be taken at least 2 hours after the initial dose. If the initial dose is ineffective, controlled clinical trials have not shown a benefit of a second dose to treat the same attack. The maximum daily dose should not exceed 80 mg.

The safety of treating an average of more than 3 headaches in a 30-day period has not been established.